The FDA has approved iloperidone tablets for the treatment of manic or mixed episodes associated with bipolar I disorder in adults. Iloperidone is an atypical antipsychotic that acts as a dopamine D2/serotonin 5-HT2A receptor antagonist. The approval was based on a phase 3 trial showing significant improvement in symptoms with iloperidone compared to placebo. The drug has a well-known safety profile and is effective in managing bipolar I disorder. Common side effects include tachycardia, dizziness, and weight gain. Dosage should be titrated to avoid orthostatic hypotension. The drug is contraindicated in patients with hypersensitivity reactions.
Source link
FDA Approves Iloperidone for Bipolar Disorder
